Palvella Therapeutics Inc (PVLA)

May 22, 2026

Kathleen Goin, Palvella COO, sells $475,630 in company stock By Investing.com - Investing.com Australia

May 22, 2026

May 22, 2026

Kathleen Goin, Palvella COO, sells $475,630 in company stock - Investing.com

May 22, 2026

May 22, 2026

Number of shareholders of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView

May 22, 2026

May 22, 2026

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards - Sahm

May 22, 2026

May 22, 2026

PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill

May 22, 2026

May 22, 2026

Palvella Therapeutics Q1 earnings call highlights - MSN

May 22, 2026

May 20, 2026

Palvella presents clinical data on topical rapamycin gel By Investing.com - Investing.com Nigeria

May 20, 2026

May 20, 2026

Palvella Reports Positive Phase 3 Data for QTORIN - TipRanks

May 20, 2026

May 20, 2026

Palvella presents clinical data on topical rapamycin gel - Investing.com

May 20, 2026

May 20, 2026

Palvella's QTORIN™ rapamycin shows strong Phase... | Pluang – Crypto, Stocks, Gold & Funds - Pluang

May 20, 2026

May 20, 2026

Palvella Therapeutics Reports Positive Phase 3 SELVA and Phase 2 TOIVA Study Results for QTORIN™ Rapamycin in Treating Microcystic Lymphatic Malformations and Cutaneous Venous Malformations - Quiver Quantitative

May 20, 2026

May 20, 2026

Rare vascular disease trial: 100% of children improved - Stock Titan

May 20, 2026

May 18, 2026

Palvella’s QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation - Yahoo Finance

May 18, 2026

May 16, 2026

Palvella Eyes 2027 Launch After Positive Phase 3 Results - MyChesCo

May 16, 2026

May 15, 2026

Palvella Therapeutics Reports Positive Phase 2 TOIVA Trial Results for QTORIN Rapamycin in Cutaneous Venous Malformations at SID 2026 - Minichart

May 15, 2026

May 15, 2026

Palvella presents Phase 2 data on bleeding reduction treatment - Investing.com UK

May 15, 2026

May 15, 2026

Palvella presents Phase 2 data on bleeding reduction treatment By Investing.com - Investing.com South Africa

May 15, 2026

May 15, 2026

Palvella Unveils Promising Phase 2 Data for QTORIN - TipRanks

May 15, 2026

May 15, 2026

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology - The Manila Times

May 15, 2026

May 15, 2026

Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations - TradingView

May 15, 2026

May 15, 2026

Palvella presents positive Phase 2 TOIVA data showing significant bleeding reduction with QTORIN rapamycin - TradingView

May 15, 2026

May 15, 2026

New skin trial eases bleeding in rare disease affecting over 75,000 in U.S. - Stock Titan

May 15, 2026

May 14, 2026

Palvella targets 2H 2026 NDA filing while outlining >$1B peak US sales potential for QTORIN rapamycin in microcystic lymphatic malformations - MSN

May 14, 2026

May 14, 2026

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market - Sahm

May 14, 2026

May 13, 2026

Palvella Therapeutics approved for transfer to Nasdaq Global Market - MSN

May 13, 2026

May 13, 2026

Palvella Therapeutics moves to Nasdaq Global Market By Investing.com - Investing.com India

May 13, 2026

May 13, 2026

Palvella Therapeutics Upgrades Listing to Nasdaq Global Market - Moomoo

May 13, 2026

May 13, 2026

Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Stock Information (NASDAQ: PVLA) 161851 - Minichart

May 13, 2026

May 13, 2026

Palvella Therapeutics announces uplisting to the Nasdaq Global Market - marketscreener.com

May 13, 2026

May 13, 2026

Palvella Therapeutics to transfer listing to Nasdaq Global Market By Investing.com - Investing.com India

May 13, 2026

May 13, 2026

Palvella Therapeutics to transfer listing to Nasdaq Global Market - Investing.com

May 13, 2026

May 13, 2026

Palvella Therapeutics moves to Nasdaq Global Market - Investing.com

May 13, 2026

May 13, 2026

Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market - TradingView

May 13, 2026

May 13, 2026

Palvella Therapeutics, Inc. Primary Exchange Listing will Change to Nasdaq Global Market from Nasdaq Capital Market - marketscreener.com

May 13, 2026

May 12, 2026

Palvella Therapeutics | 8-K: Current report - Moomoo

May 12, 2026

May 12, 2026

Stifel Maintains Palvella Therapeutics (PVLA) Buy Recommendation - MSN

May 12, 2026

May 12, 2026

Stephens initiates Palvella stock with overweight rating, $220 target By Investing.com - Investing.com Canada

May 12, 2026

May 12, 2026

Stephens & Co. initiates coverage of Palvella Therapeutics (PVLA) with overweight recommendation - MSN

May 12, 2026

May 09, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

May 09, 2026

May 08, 2026

Palvella Therapeutics Q1 Earnings Call Highlights - Yahoo Finance

May 08, 2026

May 08, 2026

Mizuho Trims Price Target on Palvella Therapeutics to $240 From $250, Keeps Outperform Rating - Moomoo

May 08, 2026

May 08, 2026

Palvella Therapeutics Doses First Patients in Phase 2 Trial for Rare Skin Disease - Moomoo

May 08, 2026